Core Viewpoint - 甘之草科技股份有限公司 has submitted its listing application to the Hong Kong Stock Exchange, positioning itself as a leading player in the online traditional Chinese medicine market with significant market shares in both the overall market and online diagnosis sectors [1][2]. Financial Performance - The company reported a revenue increase from 603 million RMB to 690 million RMB from 2023 to 2024, achieving profits of 1.88 million RMB and 10.16 million RMB respectively, alongside healthy cash inflows from operations [2]. - However, in 2025, despite a revenue of 554 million RMB and a gross profit of 150 million RMB in the first three quarters, the company recorded a loss of 1.24 million RMB, indicating a reversal in profitability [2]. - The cash flow from operating activities also turned negative, with a net outflow of 640,000 RMB, suggesting challenges in the company's core business operations [2]. Valuation and Capitalization - 甘之草's valuation skyrocketed from 6.775 million RMB to 1.639 billion RMB, marking an increase of over 240 times within three years, driven by aggressive institutional investments prior to its IPO [2][8]. - The first significant institutional investment occurred in late 2024, leading to a valuation surge of over 118 times, with the company’s pre-investment valuation reaching 800 million RMB [3][8]. - By early 2026, the company achieved a historic valuation of 1.639 billion RMB, with multiple investment firms participating in the final round of funding [6][8]. Shareholder Structure - As of the latest disclosure, the founder, Xu Zhiliang, holds a 34.7% stake in the company, with a diversified shareholder structure emerging from previous capital injections [2][7]. - The shareholder composition has evolved, with significant stakes held by various investors, including杭州巴戟天 and杭州星陀, reflecting a shift towards a more diversified ownership model [4][5][7]. Investment Dynamics - The capital trajectory of 甘之草 illustrates a clear pattern of institutional investment driven by expectations of capital appreciation, with a series of strategic investments leading to substantial valuation increases [8]. - The company’s capital operations are characterized by a focus on maximizing valuation ahead of its IPO, with a notable emphasis on the timing and structure of investments [6][8].